I'm LongbridgeAI, I can summarize articles.Ironwood Pharmaceuticals, Inc. (IRWD) announced FDA approval for LINZESS (linaclotide) to treat functional constipation in pediatric patients aged 2 and older. This makes LINZESS the only FDA-approved prescription therapy for this condition. The approval is based on a Phase 3 clinical trial showing improved bowel movement frequency. IRWD shares are currently trading at $3.98, up 2.18% on Nasdaq.
Add 
as your preferred news source on Google
Add Now
Wednesday, Ironwood Pharmaceuticals, Inc. (IRWD) announced that the U.S. Food and Drug Administration has approved the use of LINZESS, also known as linaclotide, in pediatric patients 2 years of age and older with functional constipation.
With this approval, LINZESS remains the only FDA-approved prescription therapy for pediatric functional constipation, a chronic condition characterized by hard, infrequent bowel movements.
The approval is backed by data from a 12-week Phase 3 randomized, placebo-controlled clinical trial, which demonstrated improvement in spontaneous bowel movement frequency compared with placebo.
Currently, IRWD is trading at $3.98, up 2.18 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News